Anti-Bacterial Agents
/ pharmacology
Azabicyclo Compounds
/ pharmacology
Cefepime
/ pharmacology
Ceftazidime
/ pharmacology
Cephalosporins
/ pharmacology
Cross Infection
/ microbiology
Drug Combinations
Drug Resistance, Bacterial
/ drug effects
Enterobacteriaceae
/ drug effects
Europe
Gram-Negative Bacteria
/ drug effects
Gram-Negative Bacterial Infections
/ microbiology
Hospitals
Humans
Microbial Sensitivity Tests
Pseudomonas aeruginosa
/ drug effects
Tazobactam
/ pharmacology
Triazoles
/ pharmacology
United States
AAI101
ESBL
beta-lactamase inhibitor
cefepime
enmetazobactam
surveillance studies
Journal
Antimicrobial agents and chemotherapy
ISSN: 1098-6596
Titre abrégé: Antimicrob Agents Chemother
Pays: United States
ID NLM: 0315061
Informations de publication
Date de publication:
07 2019
07 2019
Historique:
received:
08
03
2019
accepted:
11
04
2019
pubmed:
17
4
2019
medline:
8
5
2020
entrez:
17
4
2019
Statut:
epublish
Résumé
Enmetazobactam, formerly AAI101, is a novel penicillanic acid sulfone extended-spectrum β-lactamase (ESBL) inhibitor. The combination of enmetazobactam with cefepime has entered clinical trials to assess safety and efficacy in patients with complicated urinary tract infections. Here, the
Identifiants
pubmed: 30988152
pii: AAC.00514-19
doi: 10.1128/AAC.00514-19
pmc: PMC6591593
pii:
doi:
Substances chimiques
Anti-Bacterial Agents
0
Azabicyclo Compounds
0
Cephalosporins
0
Drug Combinations
0
Triazoles
0
avibactam, ceftazidime drug combination
0
ceftolozane, tazobactam drug combination
0
Cefepime
807PW4VQE3
enmetazobactam
80VUN7L00C
Ceftazidime
9M416Z9QNR
Tazobactam
SE10G96M8W
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
Copyright © 2019 Morrissey et al.
Références
J Infect Dis. 2017 Feb 15;215(suppl_1):S28-S36
pubmed: 28375512
J Antimicrob Chemother. 2018 Oct 1;73(10):2631-2642
pubmed: 29800480
Expert Opin Pharmacother. 2016;17(7):953-67
pubmed: 26891857
Pathogens. 2015 Aug 18;4(3):620-5
pubmed: 26295262
Expert Rev Anti Infect Ther. 2008 Dec;6(6):805-24
pubmed: 19053894
Antimicrob Agents Chemother. 2018 Sep 24;62(10):
pubmed: 30061284
Clin Microbiol Infect. 2006 May;12(5):418-25
pubmed: 16643517
Antimicrob Agents Chemother. 2010 Mar;54(3):969-76
pubmed: 19995920
Antimicrob Resist Infect Control. 2015 May 01;4:14
pubmed: 25932324
Emerg Infect Dis. 2011 Oct;17(10):1791-8
pubmed: 22000347
Antimicrob Agents Chemother. 2015 May;59(5):2688-94
pubmed: 25712356
Proc Natl Acad Sci U S A. 2018 Apr 10;115(15):E3463-E3470
pubmed: 29581252
Antimicrob Agents Chemother. 2015;59(6):3606-10
pubmed: 25801558
Clin Infect Dis. 2018 Apr 3;66(8):1290-1297
pubmed: 29165604
Infect Control Hosp Epidemiol. 2016 Nov;37(11):1288-1301
pubmed: 27573805
Antimicrob Agents Chemother. 2018 Oct 24;62(11):
pubmed: 30104282
J Antimicrob Chemother. 2017 Sep 1;72(9):2410-2417
pubmed: 28637307
J Travel Med. 2017 Apr 1;24(suppl_1):S44-S51
pubmed: 28521000
Antimicrob Agents Chemother. 2019 Apr 25;63(5):
pubmed: 30858223
JAMA. 2018 Sep 11;320(10):984-994
pubmed: 30208454
Lancet Infect Dis. 2018 Mar;18(3):318-327
pubmed: 29276051
Lancet Infect Dis. 2019 Jan;19(1):56-66
pubmed: 30409683